Full Text | PDF

Oncomedicine 2016; 1:25-27. doi:10.7150/oncm.16256 This volume Cite

Short Research Paper

ERCC1 Biomarker in Colorectal Cancer: To Induce or Not to Induce? This Is the Matter!

Mariantonietta Di Salvatore¹, Armando Orlandi^1✉, Carmela Paolillo², Francesca Aroldi³, Mariagrazia Rodriquenz¹, Ettore Capolongo², Carlo Barone¹

1. Medical Oncology Department, Università Cattolica del Sacro Cuore, Rome, Italy;
2. Department of Biochemistry, Università Cattolica del Sacro Cuore, Rome, Italy;
3. Department of Medical Oncology, Fondazione Poliambulanza, Brescia, Italy.

✉ Corresponding author: Armando Orlandi MD, PhD, Department of Medical Oncology, Università Cattolica del Sacro Cuore, Roma. Largo Gemelli, 8 - 00168 Rome, Italy. e-mail: armando.orlandirm.unicatt.it; Phone: +39 06 30156318; Fax: +39 06 30154838. More

Abstract

In this short research communication, using circulating tumor cells (CTCs) as a “dynamic” tissue, we found that ERCC1 induction is significantly correlated with clinical outcome in colorectal cancer patients treated with oxaliplain-based therapy. This is the first report proposing the ability to induce ERCC1 as a blood-based biomarker for oxaliplatin resistance in metastatic colorectal cancer.

Keywords: CTC, ERCC1, oxaliplatin, colorectal cancer

Citation styles